

Docket No.
447-US-PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Michael Didriksen, et al. Confirmation No. 5885
Application No.: 10/568,133 Group Art Unit: 1617
Filed: May 9, 2006 Examiner: Ramachandran, U.
For: THE COMBINATION OF A SEROTONIN REUPTAKE INHIBITOR
AND A GLYCINE TRANSPORTER TYPE 1 INHIBITOR FOR THE
TREATMENT OF DEPRESSION

Date: **June 1, 2007**

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Information Disclosure Statement by Applicant forms (PTO/SB/08a). In accordance with 37 C.F.R. § 1.98(a)(2)(ii) as revised at 69 Fed. Reg. 56481 (September 21, 2004), copies of the cited U.S. Patent Application Publication has not been submitted. Copies of the four (4) foreign patent documents listed on the enclosed PTO/SB/08a are enclosed herewith.

This Information Disclosure Statement is being filed before the mailing of a first Office action on the merits. Accordingly, neither a fee nor Statement under 37 C.F.R. § 1.97(e) is due. However, if a first Office Action has been mailed, authorization is given to charge the fee under 37 C.F.R. § 1.17(p) (\$180) to Deposit Account No. 50-3201.

It is respectfully requested that the above information be considered by the Examiner and that an initialed copy of the accompanying Information Disclosure Statement by Applicant form (PTO/SB/08a) be returned to the undersigned indicating that such information has been considered.

**U.S. Serial No. 10/568,133
Information Disclosure Statement
Filed June 1, 2007**

If a telephone interview would be of assistance in advancing prosecution of the above-identified application, applicants' undersigned attorney invites the Examiner to telephone the number provided below.

No fee is deemed necessary in connection with filing this Information Disclosure Statement. However, if a fee is required, authorization is hereby given to charge this fee to Deposit Account Number 50-3201.

Respectfully submitted,



Stephen G. Kalinchak
Reg. No. 38,747
Lundbeck Research USA, Inc.
215 College Road
Paramus, New Jersey 07652
Tel: 201-350-0781
Fax: 201-225-9571